Cargando…
A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology
Background and Objectives: Biological therapy is widely used for the treatment of severe psoriasis. The objective of this study was to evaluate the efficacy and safety of biological therapy for patients with severe psoriasis. Materials and Methods: A retrospective study of 79 patients with severe ps...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353857/ https://www.ncbi.nlm.nih.gov/pubmed/32512854 http://dx.doi.org/10.3390/medicina56060275 |
_version_ | 1783557971423264768 |
---|---|
author | Raudonis, Tadas Gliebute, Akvile Grigaityte, Anna Greta Lukosiunaite, Zivile Karmaziene, Tatjana Grigaitiene, Jurate |
author_facet | Raudonis, Tadas Gliebute, Akvile Grigaityte, Anna Greta Lukosiunaite, Zivile Karmaziene, Tatjana Grigaitiene, Jurate |
author_sort | Raudonis, Tadas |
collection | PubMed |
description | Background and Objectives: Biological therapy is widely used for the treatment of severe psoriasis. The objective of this study was to evaluate the efficacy and safety of biological therapy for patients with severe psoriasis. Materials and Methods: A retrospective study of 79 patients with severe psoriasis, who have been treated with biological therapy between 2012 and 2018, was conducted. During this study, the following data were collected and evaluated: sex, age, body mass index (BMI), duration of illness, the results of treatment with biological therapy, concomitant therapy, Psoriasis Area and Severity Index (PASI) and adverse events. Results: In total, 74.7% (n = 59) of subjects were male. Their overall average age was 47.4 ± 11.4 (range: 18–73) years. Their baseline BMI was 27.6 ± 5.9, which increased to 29.6 ± 4.5 after 6 years of treatment. The mean duration of psoriasis was 25.7 ± 12.5 years. In total, 39.2% (n = 31) of subjects received infliximab, 36.7% (n = 29)—etanercept, 24.1% (n = 19)—ustekinumab. The treatment duration for infliximab, etanercept and ustekinumab was 201.6 ± 86.8, 156.2 ± 137.4 and 219.1 ± 95.7 weeks (p < 0.01), respectively. Overall, 65.8% (n = 52) of subjects were also on methotrexate; 30.8% (n = 16) of them discontinued it due to clinical improvement (31.3% (n = 5)), impaired liver function (31.3% (n = 5)), and intolerance (25% (n = 4)). Baseline PASI was 20.8 ± 8.8. PASI 50 was achieved by 96.2% (n = 76) of patients at week 11, PASI 75 by 86.1% (n = 68) at week 16, PASI 90 by 54.4% (n = 43) at week 35, and PASI 100 by 13.9% (n = 11) at week 33. The overall incidence rate of adverse events was 0.362 per patient year of follow-up. Conclusion: Biological therapy is an effective and safe treatment for patients with severe psoriasis. |
format | Online Article Text |
id | pubmed-7353857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-73538572020-07-21 A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology Raudonis, Tadas Gliebute, Akvile Grigaityte, Anna Greta Lukosiunaite, Zivile Karmaziene, Tatjana Grigaitiene, Jurate Medicina (Kaunas) Review Background and Objectives: Biological therapy is widely used for the treatment of severe psoriasis. The objective of this study was to evaluate the efficacy and safety of biological therapy for patients with severe psoriasis. Materials and Methods: A retrospective study of 79 patients with severe psoriasis, who have been treated with biological therapy between 2012 and 2018, was conducted. During this study, the following data were collected and evaluated: sex, age, body mass index (BMI), duration of illness, the results of treatment with biological therapy, concomitant therapy, Psoriasis Area and Severity Index (PASI) and adverse events. Results: In total, 74.7% (n = 59) of subjects were male. Their overall average age was 47.4 ± 11.4 (range: 18–73) years. Their baseline BMI was 27.6 ± 5.9, which increased to 29.6 ± 4.5 after 6 years of treatment. The mean duration of psoriasis was 25.7 ± 12.5 years. In total, 39.2% (n = 31) of subjects received infliximab, 36.7% (n = 29)—etanercept, 24.1% (n = 19)—ustekinumab. The treatment duration for infliximab, etanercept and ustekinumab was 201.6 ± 86.8, 156.2 ± 137.4 and 219.1 ± 95.7 weeks (p < 0.01), respectively. Overall, 65.8% (n = 52) of subjects were also on methotrexate; 30.8% (n = 16) of them discontinued it due to clinical improvement (31.3% (n = 5)), impaired liver function (31.3% (n = 5)), and intolerance (25% (n = 4)). Baseline PASI was 20.8 ± 8.8. PASI 50 was achieved by 96.2% (n = 76) of patients at week 11, PASI 75 by 86.1% (n = 68) at week 16, PASI 90 by 54.4% (n = 43) at week 35, and PASI 100 by 13.9% (n = 11) at week 33. The overall incidence rate of adverse events was 0.362 per patient year of follow-up. Conclusion: Biological therapy is an effective and safe treatment for patients with severe psoriasis. MDPI 2020-06-04 /pmc/articles/PMC7353857/ /pubmed/32512854 http://dx.doi.org/10.3390/medicina56060275 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Raudonis, Tadas Gliebute, Akvile Grigaityte, Anna Greta Lukosiunaite, Zivile Karmaziene, Tatjana Grigaitiene, Jurate A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology |
title | A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology |
title_full | A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology |
title_fullStr | A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology |
title_full_unstemmed | A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology |
title_short | A Six-Year Analysis of Biological Therapy for Severe Psoriasis in a Lithuanian Reference Centre of Dermatovenereology |
title_sort | six-year analysis of biological therapy for severe psoriasis in a lithuanian reference centre of dermatovenereology |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7353857/ https://www.ncbi.nlm.nih.gov/pubmed/32512854 http://dx.doi.org/10.3390/medicina56060275 |
work_keys_str_mv | AT raudonistadas asixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology AT gliebuteakvile asixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology AT grigaityteannagreta asixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology AT lukosiunaitezivile asixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology AT karmazienetatjana asixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology AT grigaitienejurate asixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology AT raudonistadas sixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology AT gliebuteakvile sixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology AT grigaityteannagreta sixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology AT lukosiunaitezivile sixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology AT karmazienetatjana sixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology AT grigaitienejurate sixyearanalysisofbiologicaltherapyforseverepsoriasisinalithuanianreferencecentreofdermatovenereology |